Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease

Hida, Yasutoshi; Kubo, Yoshiaki; Murao, Kazutoshi; Arase, Seiji

doi:10.1007/s00403-006-0725-6

Cited by 146 publications

(117 citation statements)

References 17 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…SIRT1 is overexpressed in acute myeloid leukemia (AML) blasts from patients as well as AML cell lines (Bradbury et al, 2005). The overexpression found in multiple types of nonmelanoma skin cancers, including early stages, suggests that SIRT1 may be playing a critical role in promoting proliferation in skin cancer (Hida et al, 2006). The ability of cancer cells to undergo senescence correlates with their response to treatment.…”

Section: Sirt1 Promotes Replicative Senescence During Prolonged Exposmentioning

confidence: 99%

“…Tumor cells show global changes in their chromatin, which can in part be due to the dysregulation of sirtuins (Jones and Baylin, 2007). Overexpression of SIRT1, SIRT2, SIRT3 and SIRT7 are found in tumors (De Nigris et al, 2002;Hiratsuka et al, 2003;Bradbury et al, 2005;Ashraf et al, 2006;Hida et al, 2006), indicating that sirtuin inhibitors may be useful chemotherapeutic agents against cancers that overexpress these sirtuins. The increased acetylation of targets, such as p53, Foxo, Ku70 and BCL6 induced by inhibition of sirtuins, in conjunction with chemotherapy agents that damage DNA, might induce tumor cell apoptosis.…”

Section: Therapeutic Potential Of Sirtuin Regulationmentioning

confidence: 99%

See 1 more Smart Citation

Sirtuins: critical regulators at the crossroads between cancer and aging

2007

View full text Add to dashboard Cite

Sirtuins (SIRTs 1À7), or class III histone deacetylases (HDACs), are protein deacetylases/ADP ribosyltransferases that target a wide range of cellular proteins in the nucleus, cytoplasm, and mitochondria for post-translational modification by acetylation (SIRT1, -2, -3 and -5) or ADP ribosylation (SIRT4 and -6). The orthologs of sirtuins in lower organisms play a critical role in regulating lifespan. As cancer is a disease of aging, we discuss the growing implications of the sirtuins in protecting against cancer development. Sirtuins regulate the cellular responses to stress and ensure that damaged DNA is not propagated and that mutations do not accumulate. SIRT1 also promotes replicative senescence under conditions of chronic stress. By participating in the stress response to genomic insults, sirtuins are thought to protect against cancer, but they are also emerging as direct participants in the growth of some cancers. Here, we review the growing implications of sirtuins both in cancer prevention and as specific and novel cancer therapeutic targets.

show abstract

Section: Sirt1 Promotes Replicative Senescence During Prolonged Exposmentioning

confidence: 99%

Section: Therapeutic Potential Of Sirtuin Regulationmentioning

confidence: 99%

Sirtuins: critical regulators at the crossroads between cancer and aging

2007

View full text Add to dashboard Cite

show abstract

“…In our study, significantly elevated expression of sIrt1 was observed in HCC tissues when compared to non-tumor tissues. Increased expression of sIrt1 has been reported in various types of malignant tumors, including human cutaneous tumors (12), and breast (13), colon (13), prostate (14), and mouse cancers (9). In addition, sIrt1 expression has been suggested as a possible prognostic indicator in human malignant lymphoma (16) and gastric cancer (22).…”

Section: Of ---------------------------------------mentioning

confidence: 99%

“…Up-regulation of sIrt1 induces deacetylated inactivation of p53, which allows proliferation of cells in the presence of damaged DNA such that mutations accumulate, including those in p53 itself, leading to disruption of the cell cycle control and promotion of tumor progression (6)(7)(8)(9)(10)(11). recent studies have demonstrated overexpression of sIrt1 in cancer tissue, compared with normal tissue, suggesting that sIrt1 may act as a tumor promoter (9,(12)(13)(14)(15)(16). However, expression of sIrt1 in HCC and its role have not been investigated.…”

mentioning

confidence: 99%

Expression and role of SIRT1 in hepatocellular carcinoma

Choi

Bae²,

Jamiyandorj³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. silent mating type information regulation 2 homolog 1 (sIrt1) is a multifaceted, nicotinamide adenine dinucleotide-dependent protein deacetylase with involvement in a wide variety of cellular processes ranging from cancer to aging. expression of sIrt1 was evaluated in 90 cases of hepatocellular carcinoma (HCC) and five HCC cell lines. The relationship between the mutation status of p53 and expression of sIrt1 was also investigated in 10 fresh HCC tissues. synthetic small interfering rNA was used to silence sIrt1 gene expression by rNA interference (rNAi), and cell growth and cell cycle progression were assessed. expression of sIrt1 was significantly elevated in the HCC tissues when compared to that of non-tumor tissues (p<0.001). Overexpression of sIrt1 and p53 was observed in 56% (50 of 90) and in 30% (27 of 90) of the HCCs, respectively. expression of sIrt1 showed significant correlation with gender (p=0.023), serum AFP levels (p=0.030), viral infection (p=0.005) and p53 expression (p<0.021). Western blot analysis found no correlation between p53 mutation and expression levels of sIrt1. sIrt1 silencing was found to induce cell growth arrest in HCC cells. these results suggest an association of sIrt1 expression with HCC development and that sIrt1 plays a role in cancer cell growth.

show abstract

“…Accumulating evidence also point to SirT1 as having a function in cancer; however, inferences from the literature are that SirT1 has both oncogenic and tumor-suppressor activities. SirT1 was reported to be overexpressed in acute myeloid leukemia, non-melanoma skin cancer, breast cancer, colorectal carcinoma and prostate cancer (Bradbury et al, 2005;Kuzmichev et al, 2005;Hida et al, 2007;Huffman et al, 2007;Stunkel et al, 2007) and to be downregulated in glioblastoma, prostate cancer, bladder carcinoma, breast cancer, hepatocellular carcinoma and ovarian cancer (Wang et al, 2008a). It is also expressed at a high level in diffuse large B-cell lymphomas and is associated to bad prognosis (Jang et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol

et al. 2009

View full text Add to dashboard Cite

The function of the class III histone deacetylase, Sir2, in promoting lifespan extension is well established in small model organisms. By analogy, SirT1, the mammalian orthologue of Sir2, is a candidate gene to slow down aging and forestall the onset of age-associated diseases. We have used SirT1-null mice to study the function of SirT1 in susceptibility to tumorigenesis. The number of intestinal polyps induced in mice carrying the Apc min mutation was unaffected by the SirT1 genotype although the average polyp size was slightly smaller in the SirT1-null animals. Similarly, the presence or absence of SirT1 had no effect on incidence and tumor load of skin papillomas induced by the classical two-stage carcinogenesis protocol. We found that resveratrol topically applied to the skin profoundly reduced tumorigenesis. This chemoprotective effect was significantly reduced but not ablated in SirT1-null mice, suggesting that part of the protection afforded by resveratrol requires the SirT1-encoded protein. Thus, our results suggest that SirT1 does not behave like a classical tumor-suppressor gene but the antitumor activity of resveratrol is mediated at least in part by SirT1.

show abstract

Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease

Cited by 146 publications

References 17 publications

Sirtuins: critical regulators at the crossroads between cancer and aging

Sirtuins: critical regulators at the crossroads between cancer and aging

Expression and role of SIRT1 in hepatocellular carcinoma

SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol

Contact Info

Product

Resources

About